JPMorgan: Maintains "Overweight" rating on GenScript Biotech (01548.HK) with a target price of HK$41

Zhitong Finance APP has learned that JPMorgan issued a research report stating that Eli Lilly (LLY.US) announced a TuneLab cooperation agreement with GenScript Biotech (01548.HK) and others. The bank maintains GenScript's "Overweight" rating and a target price of HK$41. Among these, GenScript will provide wet lab services to TuneLab member companies, including gene synthesis, protein expression, purification, and testing according to standardized protocols, helping to translate AI-generated drug candidates into experimental results. The bank believes this will help strengthen GenScript's leading position in the AI-driven drug discovery (AIDD) ecosystem.